Mesenchymal stem cells derived from adipose tissue are not affected by renal disease  by Roemeling-van Rhijn, Marieke et al.
see commentary on page 731
Mesenchymal stem cells derived from adipose
tissue are not affected by renal disease
Marieke Roemeling-van Rhijn1, Marlies E.J. Reinders2, Annelies de Klein3, Hannie Douben3,
Sander S. Korevaar1, Fane K.F. Mensah1, Frank J.M.F. Dor4, Jan N.M. IJzermans4, Michiel G.H. Betjes1,
Carla C. Baan1, Willem Weimar1 and Martin J. Hoogduijn1
1Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands; 2Department of Nephrology, Leiden
University Medical Center, Leiden, The Netherlands; 3Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The
Netherlands and 4Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands
Mesenchymal stem cells are a potential therapeutic agent in
renal disease and kidney transplantation. Autologous cell use
in kidney transplantation is preferred to avoid anti-HLA
reactivity; however, the influence of renal disease on
mesenchymal stem cells is unknown. To investigate the
feasibility of autologous cell therapy in patients with renal
disease, we isolated these cells from subcutaneous adipose
tissue of healthy controls and patients with renal disease and
compared them phenotypically and functionally. The
mesenchymal stem cells from both groups showed similar
morphology and differentiation capacity, and were both over
90% positive for CD73, CD105, and CD166, and negative for
CD31 and CD45. They demonstrated comparable population
doubling times, rates of apoptosis, and were both capable of
inhibiting allo-antigen- and anti-CD3/CD28-activated
peripheral blood mononuclear cell proliferation. In response
to immune activation they both increased the expression of
pro-inflammatory and anti-inflammatory factors. These
mesenchymal stem cells were genetically stable after
extensive expansion and, importantly, were not affected by
uremic serum. Thus, mesenchymal stem cells of patients with
renal disease have similar characteristics and functionality as
those from healthy controls. Hence, our results indicate the
feasibility of their use in autologous cell therapy in patients
with renal disease.
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Mesenchymal stem or stromal cells (MSCs) are multipotent
fibroblastic cells that can be derived from bone marrow and
many other tissues including adipose tissue.1–3 In culture,
MSCs are rapidly proliferating, adherent cells, showing a
spindle-shaped morphology. They have colony-forming capa-
city and the ability to differentiate into osteoblasts, chon-
drocytes, and adipocytes.4 There is no specific MSC marker
and according to the criteria of the International Society of
Cellular Therapy (ISCT), cultured MSCs are characterized by a
CD14, CD45, HLADR, CD73þ , CD90þ , and CD105þ
phenotype.5 In addition, they express CD13, CD166, human
leukocyte antigen (HLA) class I and lack the endothelial
marker CD31. Recently, it is reported that freshly isolated
adipose tissue–derived MSCs are initially CD34þ and increas-
ingly express ISCT MSC markers after culture expansion.6
MSCs can modulate the immune system by inhibition of
mitogen- and allo-activated lymphocyte proliferation.7–9 This
effect is to a large extent dependent on soluble factors. MSCs
inhibit lymphocyte proliferation via the secretion of trans-
forming growth factor-b (TGF-b), interleukin (IL)-10, nitric
oxide, HLA-G, and hepatocyte growth factor,7,10–12 and the
expression of indoleamine 2,3-dioxygenase (IDO).13 MSCs
furthermore secrete trophic factors that stimulate vasculo-
genesis and angiogenesis, and aid tissue regeneration.14
As a result, MSCs receive a lot of interest in many medical
fields as a cellular therapy. Currently, MSC therapy is subject of
216 registered clinical trials (http://clinicaltrials.gov, February,
2012).
In renal disease, patients may profit from the repair
capacity and immunomodulatory potential of MSCs.15 In
kidney transplantation, MSC therapy could find use as an
induction/immunosuppressive therapy16–19 and for repair of
ischemia reperfusion injury.
There is a choice of MSC tissue source for therapeutic
applications. Although most studies have used MSCs from
bone marrow origin, adipose tissue has an advantage above
bone marrow as it is obtainable in a less invasive manner and
large numbers of cells can be cultured in less time. Another
critical choice is whether to use MSCs of autologous or
allogeneic origin. In a (pre-) transplant setting, it is crucial to
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avoid induction of HLA reactivity against a potential future
donor, and therefore exposure to allogeneic MSCs is to be
avoided. Autologous adipose tissue–derived MSCs are thus
the preferred choice of cells for use in renal disease and (pre-)
transplant patients.
Although RD is known to affect the immune system,20 it is
reported that functional regulatory T cells can be obtained
from uremic patients.21 However, it is unknown whether renal
impairment affects the functionality of MSCs. In patients with
immune thrombocytopenic purpura, systemic lupus erythe-
matosus, rheumatoid arthritis and aplastic anemia, and
numbers and/or functionality of MSCs were reported to be
impaired,22–25 whereas no influence of disease on MSCs was
found in multiple sclerosis and Crohn’s disease.26–28
There is a need to clarify whether MSCs derived from RD
patients are of the same quality as those obtained from
healthy controls to determine whether it is safe and feasible to
use autologous MSCs for RD and kidney transplant patients.
Besides the influence of RD on the intrinsic properties of
MSCs, uremic conditions found in these patients may have
an impact on MSC functionality as well. There is evidence
that uremia affects endothelial progenitor cell differentiation
and number,29,30 but it is unknown whether uremia affects
MSC functionality. Analysis of the effect of uremic conditions
on MSCs may predict the efficacy of MSCs after adminis-
tration to renal disease patients.
This is the first study reporting the effect of uremic
conditions on human MSC functionality. Furthermore, we
isolated adipose tissue–derived MSCs from RD patients and
healthy controls, and compared their expansion potential and
differentiation and immunomodulatory capacity. In addi-
tion, the genetic stability of MSCs of renal disease patients in
culture was investigated.
RESULTS
MSCs isolation
Cultures of MSCs were established by plating adipose
tissue–derived cell suspension in culture flasks. After 3 days,
non-adherent cells were removed. MSCs were successfully
isolated from all 16 healthy controls (MSC-HC) and 16 renal
disease patients (MSC-RD). MSC donor characteristics are
depicted in Table 1. Renal disease patients received standard
of care medication for renal insufficiency. Additionally used
medications are listed in the table.
Phenotypical characteristics of MSCs
Morphology. MSC-HC and MSC-RD cultured in standard
culture medium showed a similar spindle-shaped morphology
(Figure 1a).
Immunophenotype. The immunophenotype of MSC-HC
and MSC-RD was characterized by flow cytometric analysis.
In the freshly isolated cell fraction, we selected the
HLAABCþCD45CD31 fraction to obtain the non-
hematopoietic, non-endothelial cell fraction, and the
CD34þCD73þ population to study the MSCs. These fresh
MSCs further showed CD90 expression, and CD105 and
CD166 were expressed at low levels. There was no difference
between the immunophenotype of freshly isolated MSC-HC
and MSC-RD (Figure 1b).
After culture expansion, MSC cell surface markers CD13,
CD73, CD105, CD90, and CD166 were expressed in 495%
of MSC-HC and MSC-RD (Figure 1c). CD31, CD34, and
CD45 were absent, while HLA-DR was expressed at a low
level. No differences between the immunophenotypes of
cultured MSC-HC and MSC-RD were detected.
Table 1 | Characteristics of mesenchymal stem cell donors
(healthy controls and renal disease patients) at time of
sampling the adipose tissue
Healthy controls,
n=16
Renal disease
patients, n=16
Gender (F/M) 10/6 6/10
Age, years (mean, range) 54.5 (25–73) 56.2 (26–72)
BMI (mean, range) 29.8 (22–38) 27.1 (20–31)
Creatinine, mmol/l
(mean, range)
76 (65–95) 757 (240–1536)
GFR, ml/min per 1.73m2
(mean, range)a
76.8 (63–490) 10.3 (8–17)b
RRT (ND/PD/HD) (16/0/0) (6/8/2)
Duration of RRT
(months, range)c
NA 16.2 (8.4–30.3)
Diabetes mellitusd 0/16 4/16
Hypertensione 3/16 16/16
Medication usef
Anti-hypertentive drugs 3/16 16/16
Erythropoiesis-stimulating
agents
0/16 9/16
Anti-platelet drugs 1/16 5/16
Cholesterol-lowering drugs 0/16 4/16
Prednisone 0/16 2/16
Insulin 0/16 2/16
KTx indication NA
Nephrosclerosis 6
Focal segmental
glomerulosclerosis
2
Medullary cystic kidney
disease
1
Adult-onset polycystic kidney
disease
1
Rapidly progressive
glomerulonephritis
1
Henoch–Schonlein purpura 1
IgA nephropathy 1
Membranous
glomerulopathy
1
Diabetic nephropathy 1
Renal insufficiency e.c.i. 1
Abbreviations: BMI, body mass index; GFR, glomerular filtration rate; HD,
hemodialysis; KTx, kidney transplantation indication; NA, not applicable; ND, no
dialysis; PD, peritoneal dialysis; RRT, renal replacement therapy.
aGFR was calculated with the Modification of Diet in Renal Disease Study (MDRD)
calculation.
bIn the renal disease patient group, only pre-emptive patients are included.
cDuration of RRT: NA for healthy controls.
dNumber of subjects with diabetes mellitus.
eNumber of subject with therapy requiring hypertension.
fMost commonly used drugs (besides standard of care medication for renal
insufficiency).
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Serum analysis
To investigate the influence of uremia, MSCs were studied after
exposure to media containing 10% pooled human serum
derived from healthy controls (human healthy serum (H-HS))
or pre-emptive (glomerular filtration rate 15–25ml/minper
1.73m2; human pre-emptive serum, H-PS) or dialysis patients
(human dialysis serum, H-DS). The sera were tested for levels
of creatinine, urea, C-reactive protein (CRP), IL-1b, and IL-6.
Creatinine, urea, and CRP levels were significantly increased in
serum of pre-emptive renal disease patients compared with
healthy individuals (86.7 vs. 424.7mmol/l, 6.25 vs. 24.1mmol/l,
and 1.55 vs. 10.9mg/l, respectively). Creatinine was further
increased in serum of dialysis patients (920.8mmol/l) whereas
urea was still elevated compared with healthy serum but lower
than in pre-emptive serum (15.9mg/l). IL-1b and IL-6 were
increased in dialysis serum only (Figure 2).
Phenotypical characteristics of MSCs exposed to uremic
conditions
Morphology. MSC-RDs were cultured for 1 week in
medium containing 10% H-HS, H-PS, or H-DS. No
morphological changes were detected.
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Figure 1 |Characteristics of mesenchymal stem or stromal cell healthy control (MSC-HC) and mesenchymal stem or stromal cell
renal disease (MSC-RD). (a) Microscopic image of representative example of MSC-HC (left) and MSC-RD (right; original magnification
 100; n¼ 16 for MSC-HC and MSC-RD). (b) Representative example of flow cytometric analysis of cell surface marker expression on freshly
isolated MSC-HC (solid lines) and MSC-RD (dashed lines; n¼ 3 for patients and controls). Isotype IgG controls are represented by the solid
histograms. For human leukocyte antigen (HLA) class I and CD45 no isotypes could be used, as these markers were used for gating of MSC
from the cell suspension. (c) Representative example of flow cytometric analysis of cell surface marker expression on cultured MSC-HC
(solid lines) and MSC-RD (dashed lines). Solid histograms represent unstained controls (n¼ 4 for patients and controls). (d) Comparison
of cell surface marker expression in MSC-RD cultured for 1 week in serum of healthy individuals (H-HS, white bars), pre-emptive renal
disease patients (H-PS, gray bars), and dialysis patients (H-DS, black bars; n¼ 4).
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Immunophenotype. Immunophenotypical analysis of
MSC-RD was performed by flow cytometry after exposure
for 1 week to a medium containing 10% H-HS, H-PS, or
H-DS. No effects of the various sera on the immunopheno-
type of MSC-RD were detected (Figure 1d).
Proliferation potential of MSCs
Population doubling time. The proliferation potential of
MSCs of healthy controls and renal disease patients was
evaluated over four passages. MSC-RD demonstrated a mean
population doubling time of 2.7 days (range 2.2–4.0), not
significantly different from MSC-HC (2.8 days, range 2.2–4.3;
Figure 3a). The population doubling times of MSC-HC and
MSC-RD furthermore remained stable for at least 70 days of
culture (Figure 3b). Exposure of MSC-RD to human serum
led to a decrease in population doubling time to 1.9 days
(range 1.5–2.9). Culture in medium containing serum of pre-
emptive and ESRD patients had no effect on the proliferation
rate of MSC-RD (population doubling time 1.7 days (range
1.5–2.0) and 1.9 days (range 1.7–2.3), respectively; Figure 3a).
Colony-forming unit efficiency. For comparison of the
colony-forming unit (CFU) efficiency of MSC-HC and
MSC-RD, MSCs were seeded at 3.0 cells/cm2 and cultured
for 2 weeks before colonies were counted. Twenty-one
percent of MSC-HC showed CFU capacity (range
19.2–48%) vs. 21% of MSC-RD (range 14.0–30.4%), which
was not significantly different (Figure 3c).
Apoptosis analysis. Apoptosis detection was performed
using flow cytometric analysis of Annexin V staining in
combination with 7-AAD viability staining. The experiment
was performed with three MSC-HC and three MSC-RD
cultures. A representative example is shown in Figure 3d.
On an average, viable cells represented 94.6% and apoptotic
cells 4.1% of the expanded MSC-HC compared with
95% and 3.7%, respectively, of the MSC-RD, indicating
there was no difference in apoptosis rate between MSC-HC
and MSC-RD.
Functional characteristics of MSCs
Differentiation. When exposed to differentiation
medium, both MSC-HC and MSC-RD showed osteogenic
and adipogenic differentiation capacity as demonstrated
by histological detection of calcium depositions with von
Kossa staining for osteogenic differentiation and
staining of lipid droplets with oil red O for adipogenic
differentiation (Figure 4). Differentiation capacity was
not affected by exposure to uremic conditions (data not
shown).
Immunosuppressive capacities. The immunomodulatory
capacities of MSC-HC and MSC-RD were examined by the
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Figure 2 |Characteristics of the different pooled human sera used to evaluate the influence of uremia on mesenchymal stem or
stromal cell (MSC). Levels of (a) creatinine, (b) urea, (c) C-reactive protein, (d) interleukin (IL)-1b, and (e) IL-6 in pooled heat-inactivated
human serum of healthy male individuals (H-HS, white bars), pre-emptive male RD patients (H-PS, gray bars), and male dialysis patients
(H-DS, black bars). For the experiments, minimum essential medium-a (MEM-a) with 10% serum was used.
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analysis of their ability to inhibit the proliferation of allo-
antigen- and anti-CD3/CD28-activated peripheral blood
mononuclear cells (PBMCs). The effect of MSCs on allo-
antigen-activated PBMCs was evaluated in mixed lymphocyte
reaction (MLR) assays (n¼ 16) using five different MSC-
HCs, five different MSC-RD, and minimal 1-2-2 HLA-A, -B,
and -DR-mismatched PBMCs. In all experiments both MSC-
HC and MSC-RD were capable of a significant and dose-
dependent suppression of PBMC proliferation up to a 1:20
dilution. No significant difference was detected between the
suppressive function of MSC-HC and MSC-RD (Figure 5a).
The ability of MSC-HC and MSC-RD to inhibit the
proliferation of activated PBMCs was confirmed by adding
MSCs to anti-CD3/CD28-activated PBMCs. MSC-HC
and MSC-RD showed a significant and similar inhibition
of anti-CD3/CD28-activated PBMCs at ratios of 1:2.5–1:40
(Figure 5b).
We next examined whether uremic serum containing
medium affected the immunosuppressive effect of MSCs.
Although MSC survival and proliferation was unaffected by
uremia, PBMCs showed a severely reduced proliferation
capacity after stimulation with allogeneic PBMCs in a medium
containing serum from dialysis patients. Therefore, no
inhibitory effect of MSCs could be determined (Figure 5c).
Proliferation of PBMCs was preserved after stimulation with
anti-CD3/CD28 in a medium containing serum of pre-
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Figure 3 |Proliferation, colony-forming unit (CFU) capacity, and apoptosis of mesenchymal stem or stromal cell healthy control
(MSC-HC) and mesenchymal stem or stromal cell renal disease (MSC-RD). (a) Comparison of population doubling times
of MSC-HC and MSC-RD cultured in 15% fetal bovine serum (FBS), of MSC-RD in 10% healthy human serum (H-HS), pre-emptive RD patients
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in MSC-HC (left) and MSC-RD (right) under standard culture conditions (n¼ 3).
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emptive RD patients, whereas proliferation was reduced but
detectable when exposed to 10% dialysis serum. MSCs were
capable of further inhibiting the proliferation of anti-CD3/
CD28-stimulated PBMC proliferation in 10% pre-emptive and
dialysis serum, demonstrating that PBMCs functionality was,
but MSC functionality was not, affected by uremic conditions.
To summarize, MSCs maintained their inhibitory effect on
PBMC proliferation under uremic conditions (Figure 5d).
Expression of pro-inflammatory and anti-inflammatory gene
products. MSCs respond to inflammatory conditions with
an increase in the expression of both pro- and anti-
inflammatory factors. To compare the capacity of MSC-HC
and MCS-RD to respond to inflammatory stimuli, MSCs
were cultured with allo-antigen-activated PBMCs (MLR) in a
transwell system. MSC-RDs were furthermore cultured in
serum of pre-emptive renal disease and dialysis patients.
After 1 and 3 days MSCs were harvested and mRNA was
isolated. MSC-HC and MSC-RD cultured in the different
sera showed a similar response to the pro-inflammatory
conditions. They increased expression of anti-inflammatory
IDO and programmed death ligand 1, while the expression of
TGF-b was mildly reduced (Figure 5e). The expression of the
pro-inflammatory cytokines IL-1b, IL-6, and IL-8 was
increased in all MSCs tested, demonstrating that MSC-HC
and MSC-RD follow the same trend in gene expression in
response to inflammatory stimuli (Figure 5e). MSC-RD
exposed to 10% uremic sera showed the same gene
expression profile as MSC-RD in healthy serum, except for
IL-1b, which was induced at lower levels after 1 day of culture
with MLR (Figure 5f).
Cytogenetic and molecular genetic analysis of expanded
MSC-RD
As genomic stability of MSCs is crucial for their use in future
clinical trials, SNP array–based whole-genome analysis of
three expanded MSC-RD was performed. As a control the
non-cultured PBMCs of the MSC donor were used. Using a
window of three SNP or 50 kb, we did not detect any copy
number variations (CNVs) among the PBMC/MSC pairs.
Even on the single SNP level we did not observed a significant
change in SNP calling (i.e., o2 out of 317,000).
Karyotyping of cultured MSC-HC and MSC-RD revealed
only normal karyotypes.
In addition, fluorescence in situ hybridization was
performed on five MSC cultures (three healthy controls
(aged 62, 64, and 56 years) and three renal disease patients
(age 26, 37, and 77 years)), which were all cultured for 10
population doublings. The results indicated karyotypic
normal diploid cells in 495% of MSCs of both healthy
controls and RD patients (representative example of diploid
cell in Figure 6). A small number of tetraploidic MSCs was
detected. This has been described previously.31
DISCUSSION
In this study we investigated the effects of kidney disease on
adipose tissue–derived MSCs. Kidney disease is characterized
not only by a systemic accumulation of creatinine and urea
but also by associated chronic inflammation, shown by high
levels of CRP in patients with RD.32 Uremic conditions and
systemic inflammation have a clear impact on human health.
On the cellular level, kidney disease impairs the functioning
of immune cells, as we confirmed in the present study by
showing a decreased proliferative response to allo-activation
of PBMCs in uremic serum. In contrast, in vitro exposure of
MSCs to uremic conditions did not compromise the
proliferation rate, differentiation, or immunomodulatory
capacity of MSCs. This is the first study that indicates that
MSCs are resistant to high levels of uremia. Earlier we
demonstrated that adipose tissue–derived MSCs increased
their immunosuppressive capacity, when stimulated with the
Figure 4 |Differentiation capacity of mesenchymal stem or stromal cell healthy control (MSC-HC) and mesenchymal stem or
stromal cell renal disease (MSC-RD). (a) Osteogenic differentiation of MSC-HC (left) and MSC-RD (right) was determined after culturing for
3 weeks under osteogenic conditions by von Kossa staining (original magnification  100; n¼ 3). (b) Adipogenic differentiation of MSC-HC
(left) and MSC-RD (right) was determined after culturing for 2 weeks under adipogenic conditions by oil red O staining (original
magnification  100; n¼ 3).
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Figure 5 | Immunomodulatory effect of mesenchymal stem or stromal cell healthy control (MSC-HC; n¼ 5) and mesenchymal stem
or stromal cell renal disease (MSC-RD; n¼ 5). (a) Inhibition of the proliferation of allo-activated PBMCs (mixed lymphocyte reaction (MLR),
minimal 1-2-2 human leukocyte antigen (HLA)-A, -B, and -DR mismatched) by MSC-HC and MSC-RD (n¼ 16). (b) Inhibition of the
proliferation of anti-CD3/CD28 stimulated PBMCs by MSC-HC and MSC-RD (n¼ 12). (c) Inhibition of the proliferation of allo-activated PBMCs
(MLR, minimal 1-2-2 HLA-A, -B, and -DR mismatched) by MSC-RD in human serum of healthy individuals, pre-emptive RD patients and of
patients on dialysis (n¼ 6). (d) Inhibition of the proliferation of anti-CD3/CD28-stimulated PBMCs by MSC-RD in the three sera. *Po0.05,
**Po0.01, compared with no MSCs in the corresponding serum (n¼ 3). (e) mRNA expression of anti-inflammatory (indoleamine 2,3-
dioxygenase (IDO), transforming growth factor-b (TGF-b), and programmed death ligand 1 (PD-L1)) and pro-inflammatory (interleukin (IL)-1b, IL-
6, and IL-8) genes by MSCs after stimulation with allo-activated PBMCs (MLR). Data shown represent the fold change in the expression
compared with control MSCs cultured without MLR (MSC-HC n¼ 5, MSC-RD n¼ 4). (f) mRNA expression of IDO, TGF-b, PD-L1, IL-1b, IL-6, and
IL-8 genes by MSC-RD after 3-day stimulation with allo-activated PBMCs (MLR; mean fold change in expression compared with control MSCs
cultured without MLR) in medium containing 10% human healthy serum (H-HS), human pre-emptive serum (H-PS), or human dialysis serum
(H-DS; n¼ 3). CPM, counts per minute.
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pro-inflammatory cytokines IFN-g, TNF-a, and IL-6.33 In
the present study, we found no effect of serum of RD patients
on the immunosuppressive capacity of MSCs. This suggests
that the uremic and inflammatory conditions in RD patients
do not compromise the immunosuppressive function of
MSCs.
In addition, MSCs of renal disease patients did not differ
phenotypically and functionally from MSCs of healthy
individuals. Immediately after isolation from adipose tissue,
the immunophenotype of renal disease MSCs was indis-
tinguishable from MSCs of healthy individuals. After culture
expansion both MSC-HC and MSC-RD adapted to the ISCT
immunophenotypes, which remained stable in culture. Their
proliferation rate was rapid and non-declining, which would
guarantee that sufficient numbers of MSCs of RD patients
can be generated in short amount of time. Our results
therefore indicate that renal disease has no intrinsic and
extrinsic effect MSCs. This is important for the feasibility of
clinical application of autologous MSCs in renal disease
patients.
An important matter of concern for cellular therapy is the
genetic stability of the cells in culture. Studies reporting
malignant transformation of MSCs in culture34,35 have
recently been retracted as the cultures investigated were
contaminated with tumor cell lines.36 This strengthens the
hypothesis that MSCs are genetically stable.37 Nevertheless,
screening for genetic stability remains important to ensure
that healthy cells are put back into patients, particularly when
the cells have been derived from a diseased milieu. The CNV
analysis as carried out in the present study is very suitable for
this purpose.
Whether MSCs used for cell therapy should be of
allogeneic or autologous origin is a delicate question. It has
been suggested that autologous cell usage harbors the risk for
homing of malignant cells. However, we recently found that
autologous MSCs are susceptible to lysis by NK cells38 and
are therefore unlikely to be of greater risk for tumor
formation than allogeneic cells. Although allogeneic
MSCs are more practical and cost effective, as they can be
cultured in advance and used as an off-the-shelf
product, their use may have some hazards. It has been
demonstrated that allogeneic MSCs can be immunogeneic.39
Whether potential immunogenicity of MSCs would hamper
their clinical effects is unknown. In clinical organ transplan-
tation, however, the introduction of foreign HLA might
trigger senitization against a potential future donor organ. At
this point in time, therefore, MSC therapy with autologous
cells is recommended in RD patients. When there is more
known about the development of senitization against
allogeneic MSCs, therapy with allogeneic MSCs may become
preferable.
We have demonstrated that MSCs can be successfully
isolated and expanded from adipose tissue of RD patients
and that these MSCs are fully functional, even under uremic
conditions. These results remove one of the barriers for
developing therapies with autologous MSCs in RD.
MATERIALS AND METHODS
Sources of adipose tissue
Pre kidney transplantation patients (renal disease patients; n¼ 16)
and healthy live kidney donors (healthy controls; n¼ 16) were
included after written informed consent, as approved by the Medical
Ethical Committee of the Erasmus MC (protocol no. MEC-2006-
190). Their characteristics are shown in Table 1 (glomerular
filtration rate was calculated using the MDRD Study equation).
During the kidney donation and transplantation procedure,
subcutaneous adipose tissue was surgically removed from the
abdominal incision and collected in minimum essential medium-a
(MEM-a; Invitrogen, Paisley, Scotland) with 100 IU/ml penicillin
and 100 mg/ml streptomycin (p/s; Invitrogen).
MSCs isolation, culture, and differentiation
MSCs from renal disease patients (MSC-RD) and healthy controls
(MSC-HC) were isolated from the adipose tissue as described
previously.3,40 In brief, adipose tissue was mechanically disrupted,
enzymatically digested with sterile 0.5mg/ml collagenase type IV
(Sigma-Aldrich, St Louis, MO) in RPMI-1640 þ glutaMAX
(Invitrogen) and p/s for 30min at 37 1C. For the characterization
of freshly isolated MSCs, erythrocytes were lysed with RBC lysis
buffer (BD Biosciences, San Jose, CA) according to protocol. For
culture expansion, cells were resuspended in MSC culture medium,
consisting of MEM-a with 1% p/s and 15% fetal bovine serum
(BioWhittaker, Verviers, Belgium), transferred to a 175-cm2 culture
flask (Greiner Bio-one, Essen, Germany) and kept at 37 1C, 5% CO2,
95% humidity. Medium was changed every 3–4 days. When 490%
confluent, MSCs were detached using 0.05% trypsin–EDTA at 37 1C.
Different MSC cultures were used for experiments between passages
1 and 5.
To confirm the differentiation capacity of MSCs, osteogenic and
adipogenic differentiation was induced as described previously.40
Proliferation
For calculation of population doubling time, MSCs were seeded at a
density of 1000 cells/cm2 and cultured until 90% confluency was
reached, after which the cells were detached by trypsinization,
counted and reseeded.
CFU assay
MSCs were seeded at 50 cells per 6 cm diameter culture dishes in
quintuple (3.0 cells/cm2). After 2 weeks of culture, medium was
Figure 6 | Fluorescence in situ hybridization (FISH) analysis:
representative example of three diploid cells. The
4,6–diamidino-2–phenylindole (DAPI) counterstained nuclei are
visible. In each nucleus two green spots (centromere 3 signal) and
two red spots (centromere 8) can be detected.
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removed, the dishes washed once with 1 PBS and fixed in 70%
ethanol for 5min. Colonies were stained with 2.3% Crystal violet
solution (Sigma-Aldrich) for 30min. Dishes were then washed with
tap water and colonies (41mm) were counted. CFU efficiency was
expressed as the percentage of cells capable of forming colonies.
Flow cytometric characterization of MSCs
MSCs were immunophenotyped immediately after isolation or after
culture expansion. Cultured cells were trypsinized and washed with
FACSFlow (BD Biosciences). Cell suspensions were incubated with
mouse-anti-human monocolonal antibodies against CD13-PECy7,
CD45-PERCP, HLA-DR-FITC, HLA-ABC-APC (all BD Biosciences),
CD14-PE (Serotec, Oxford, UK), CD31-FITC, CD73-PE, CD166-PE
(BD Pharma, San Jose, CA) CD90-APC, and CD105-FITC (R&D
Systems, Abingdon, UK) at room temperature in the absence of light
for 15min. After two washes with FACSFlow, flow cytometric
analysis was performed using an eight color FACSCANTO-II with
FACSDIVA Software (BD Biosciences) and FlowJo Software (Tree Star,
Palo Alto, CA). Appropriate IgG antibodies were used (BD
Pharmingen, San Jose, CA) for isotype control. For apoptosis
analysis, an Annexin V-PE apoptosis Detection Kit I (BD
Pharmingen) was used according to the manufacturer’s description.
PBMCs isolation
PBMCs were collected from buffy coats of healthy blood bank
donors (different than the MSC donors). PBMCs were isolated by
density gradient centrifugation using Ficoll Isopaque (d¼ 1.077,
Amersham, Uppsala, Sweden) and frozen at 135 1C until use.41
Serum collection
Serum of pre-emptive male renal disease patients listed for kidney
transplantation was collected and pooled from 10 individuals (H-
PS). Furthermore, serum of male patients with terminal renal
insufficiency who received renal replacement therapy by hemodialyis
was collected just pre dialysis and pooled from 10 individuals
(H-DS). Control serum was collected from male healthy individuals
(blood bank donors) and pooled from 7–10 individuals (H-HS).
All sera were heat inactivated and were tested for creatinine, CRP,
urea, and IL-1b and IL-6 levels.
Mixed lymphocyte reactions
In MLRs, 5 104 PBMCs were seeded in round-bottom 96-well
plates and stimulated with 5 104 g-irradiated (40Gy) HLA-A, -B,
and -DR-mismatched PBMCs in MEM-a with p/s and 10% heat-
inactivated human serum (pre-emptive, dialysis, or healthy). MSCs
were added to the MLR at 1:2.5, 1:5, 1:10, 1:20, and 1:40 ratios. On
day 7, proliferation was measured by incorporation of 3H-thymidine
(0.5 mCi/well, 8-h incubation) using a b-plate reader (LKB,
Bromma, Sweden).
To determine the proliferation capacity of the PBMC, 5 104
cells were stimulated with 1 mg/ml phytohemagglutinin (Murex
Biotech, Kent, UK) for 3 days and 3H-thymidine incorporation
measured. Only results of PBMCs with sufficient proliferation
capacity (410,000 c.p.m.) were included. Experiments were per-
formed in triplicate and medians were used for further analysis.
Anti-CD3/CD28 lymphocyte stimulation assay
PBMCs were stimulated with anti-human-CD3 (0.5 ml/5 105.
cells), anti-human-CD28 (0.5 ml/5 105 cells), and goat-anti-mouse
antibody (1ml/5 105 cells) for cross-linking (all BD Pharmingen).
PBMCs were seeded in round-bottom 96-well plates at 5 104 cells
per well and MSCs were added at 1:2.5, 1:5, 1:10, 1:20 and 1:40
ratios in MEM-a with p/s and 10% heat-inactivated human serum
(pre-emptive, dialysis or healthy).
On day 3, proliferation was measured by incorporation of 3H-
thymidine using a b-plate reader (LKB). Only results of PBMCs with
sufficient proliferation (410,000 c.p.m.) were included. All experi-
ments were performed in triplicate and medians were used for
further analysis.
Real-time RT-PCR
MSCs were seeded in six-well plates at 2 105 per well in the
presence or absence of an MLR separated from the MSCs by a
transwell system (1 106 responder  1 106 stimulator PBMCs,
HLA-A, -B, and -DR-mismatched). At day 0, 1, day 3, MSC cell
pellets were harvested. RNA was isolated and cDNA synthesized as
described previously.42 Quantitative expression was determined by
real-time RT-PCR using universal PCR mix (Invitrogen) and Assays-
on-demand for IDO (Hs00158627.m1), PDL-1 (H200204257.m1),
TGF-b (Hs00171257.m1), IL-1b (Hs01555410.m1), IL-6
(Hs00174131.m1), and IL-8 (Hs00174114.m1; all Applied Biosys-
tems, Foster City, CA) on an ABI PRISM 7700 sequence detector
(Applied Biosystems). Expression levels were calculated as ratio per
18S RNA or as copies mRNA per 500 ng of total RNA.
Screening genetic stability
Cytogenetic and molecular analysis. GTG-banded chromo-
somes were prepared following standard procedures, and karyotypes
were described following the recommendations for cytogenetic
nomenclature.43
Fluorescence in situ hybridization analysis. From five control
and three renal disease patients, part of the cultured MSC cells were
used for dual-color fluorescence in situ hybridization using centro-
meric chromosome 3 and 8 probes. DNA of the plasmids probes
Pa3.5(centromere 3) and D8Z2 centromere 8) were labeled with the
Random Prime labeling system (Invitrogen, Carlsbad, CA) using Bio-
16-dUTP or Dig-11-dUTP (Roche Applied Science, Indianapolis, IN).
Of each probe 5 ng labeled product was mixed denatured and
hybridized overnight at 37 1C. Next day the slides were washed (2
SSC and 0.1 SSC, 0.1% Tween) at 55 1C and incubated with
Streptadivine Alexa 594 and anti-Digoxiginine FITC for 2 h. After
washing (2 SSC, 0.1 SSC, 55 1C) the slides were counterstained
with 4,6–diamidino-2–phenylindole (DAPI, Sigma-Aldrich, Zwijn-
drecht, The Netherlands) and mounted in anti-fade solution (Dabco-
Vectashield 1:1(Vector Laboratories, Burlingame, CA)).
For each hybridization, a minimum of 300 nuclei were scored
with an Axioplan 2 Imaging microscope (Carl Zeiss, Sliedrecht, The
Netherlands) using a chroma-sp-100 DAPI and a chroma-sp-103v1
red filter (Chroma Technology, Bellows Falls, VT) and the images
were captured with the ISIS software (Metasystems, Altlussheim,
Germany).44,45
DNA isolation. DNA was isolated from frozen PBMCs
(10 106) and MSCs (10 106) using the QIAamp DNA mini-kit
(Qiagen, Valencia, CA) according to the manufacturer’s instructions.
The DNA quantity was measured using the NanoDrop ND-1000
Spectrophotometer (NanoDrop Technologies, Wilmington, DE).
High-density SNP-based oligonucleotide array analysis.
Whole-genome analysis using Illumina cyto-SNP bead chip version
12.2 (Illumina, San Diego, CA) array was performed on DNA
derived from MSC-RD expanded roughly 1000-fold in culture.
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Genomic DNA (200 ng) from the PBMC and MSC sample was
processed using reagents and protocols as described by the supplier.
The data were analyzed using Beadstudio software (Illumina), which
allows for the visualization of several different variables relevant to
the detection of copy number alterations (CNAs), including the B-
allele frequency and log R ratio.46 The normalized intensity ratio for
each SNP in the samples was compared with a 40 CEU HapMap
reference set. The B-allele frequency and log R ratio output data
were also analyzed and visualized for copy number alterations by
using the software program Nexus Copy Number (Nexus BioDis-
covery, El Segundo, CA). Results were compared with an in-house
database of known CNVs, and the public available CNVs dataset
containing B3500 healthy controls (DGV Dataset of Genomic
Variants and CHOPS data base).
In addition to the paired analysis for deletions and duplications
in MSCs vs. PBMC DNA, we also looked for non concordance for
each SNP marker present on the array using the Genomestudio GT
paired analysis settings.
Statistical analysis
Data were analyzed using the (two-tailed) Wilcoxon signed-rank
test. Statistical significance was defined as Po0.05.
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